Detalhe da pesquisa
1.
Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy.
JAMA Netw Open
; 5(1): e2144750, 2022 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35072719